



Stroke and Atrial Fibrillation

Health and Economic Burdens of Stroke and Atrial Fibrillation

Stroke is the number five cause of death and a leading cause of long-term disability in the U.S.¹ It accounted for 1 in every 20 deaths in 2013 and costs the U.S. an estimated \$33 billion each year.² A stroke is caused when the blood supply to the brain is suddenly interrupted, usually because a blood vessel bursts (hemorrhagic stroke) or is blocked by a clot (ischemic stroke).³ As a result, brain tissue is damaged due to the lack of oxygen and nutrients.³

The most common symptom of stroke is a sudden weakness or numbness of the face, arm or leg, typically on one side of the body.³ Other recognizable symptoms include: difficulty speaking or understanding speech; difficulty seeing with one or both eyes; difficulty walking, dizziness, loss of balance or coordination; severe headache with no known cause; and fainting or unconsciousness.³ Stroke is a global epidemic; more than 15 million people worldwide suffer from a stroke each year,⁴ and about 85 percent of all stroke-related deaths are registered in low- and middle-income countries.⁵ These countries also account for 87 percent of total losses due to stroke in terms of disability-adjusted life years.⁵ It is currently the No. 1 cause of death in a number of emerging economies, including China.⁶

Approximately one-half of stroke survivors are left with some degree of physical or cognitive impairment.⁵ As a result, they may need support for common activities of daily living (ADL), which directly impacts their quality of life and their relatives who often take on the role of caregiver.⁵ It is important to recognize the significance of such informal care, as it is relevant in maintaining stroke survivors in the community and providing a valuable economic resource for health care systems.⁵

Stroke Due to Atrial Fibrillation

There are a number of risk factors for developing stroke including, but not limited to, obesity, diabetes, cigarette smoking, and cardiovascular disease. One such cardiovascular (CV) condition called atrial fibrillation (AF), a type of irregular heartbeat, is a significant risk factor.⁷ A particular type of AF, known as non-valvular atrial fibrillation (NVAf), (or AF not caused by a heart valve problem), can be fatal and is the cause of about 15 percent of all ischemic strokes and as many as 30 percent of strokes occurring in people in their 80s.⁸ Recent estimates in the U.S. has AF affecting an estimated 2.6 to 3 million Americans;⁹ with approximately 795,000 people experiencing a new or recurrent stroke each year.¹⁰

Worldwide in 2010, an estimated 33.5 million individuals had AF, with close to 5 million new cases each year.¹¹

KEY TAKEAWAYS

Stroke is a global epidemic affecting more than 15 million people worldwide.⁴


Stroke is the No. 5 cause of death and a leading cause of long-term disability in the U.S. It accounted for 1 in every 20 deaths in 2013.^{1,2}

Atrial fibrillation alone is estimated to cost \$6.65 billion per year (2005 dollars).⁵

Atrial fibrillation may lead to significant negative health outcomes, including a fivefold increased risk of stroke, as well as hospitalization, impaired quality of life, and decreased work productivity. Stroke is a costly disease from individual, family, and societal perspectives. The health consequences of AF-related stroke can be devastating. Outcomes in patients with AF-associated events (e.g., thromboembolic infarctions) are often poor, and may result in severe permanent neurologic deficit or death.

Age is one of the most substantiated risk factors for stroke; therefore the aging of the world population leads to a growing number of persons at risk. Stroke risk attributable to atrial fibrillation (AF) also increases with age, rising from 1.5 percent in patients aged 50 to 59 years to 23.5 percent for patients aged 80 to 89 years.² Consequently, it is the elderly who are at greatest risk for stroke and its clinical, economic, and social burdens.

Stroke risk attributable to atrial fibrillation (AF) increases with age.




Go, A.S., et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. *Circulation*. 2013;127:e6-245.

Cost Burdens

- In the U.S., the total direct and indirect cost of stroke in 2010 was estimated to be \$53.9 billion.¹²
- In the 27 EU countries, total annual cost of stroke is estimated at €27 billion (\$36.1 billion): €18.5 billion (68.5 percent) for direct and €8.5 billion (31.5 percent) for indirect costs. A further sum of €11.1 billion (\$14.8 billion) is calculated as the value of informal care.⁵
- Stroke was the third fastest growing area of global disease burden in terms of absolute number of premature deaths between 1990 and 2010.¹³
- It is estimated that ischemic stroke alone will cost the U.S. an astounding \$2.2 trillion between 2005 to 2050.¹⁴
- A study showed the estimated annual cost of AF treatment in 2005 U.S. dollars was \$6.65 billion.¹⁵

Health and Economic Burden of Stroke in the US



*Kochanek KD, Xu JQ, Murphy SL, Miniño AM, Kung HC. Deaths: final data for 2009 [PDF-2M]. *National Vital Statistics Reports*. 2011;60(3).
 **Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation*. 2012;125(1):e2-220.
 ***Heart Disease and Stroke Prevention – Addressing the Nation’s Leading Killers: At A Glance 2011, CDC <http://www.cdc.gov/chronicdisease/resources/publications/AAG/dhdsp.htm>

Current Treatments in Stroke Prevention and Treatment

The World Health Organization (WHO) recommends drug therapy for prevention and control of heart attacks and strokes because it is feasible, high impact, and affordable (even in low- and middle-income countries).¹⁶ Drug therapy is considered more cost-effective than conventional single-risk factor interventions that address only hypertension or hypercholesterolemia.¹⁶

The American Heart Association and the European Society of Cardiology have developed treatment guidelines for AF/stroke based upon stroke severity, other underlying medical issues, and the length of the AF disease. For most patients, medication has proven to be a highly effective option.¹⁷ Untreated AF may lead to abnormal heart rhythm that can be difficult to treat. Thus, additional medicines may also be prescribed in order to control heart rate and rhythm in longterm, untreated AF patients.¹⁷ Medications are often prescribed to not only treat AF, but also to prevent blood clots that can lead to a stroke. Medication options include blood thinners (e.g., antiplatelet, anticoagulant), heart rate controllers (e.g., beta blockers, calcium channel blockers), and heart rhythm controllers (e.g., sodium and potassium channel blockers). Such treatments can help to significantly reduce both the direct and indirect negative health outcomes, as well as the costs associated with untreated AF.⁹

Endnotes

1. Centers for Disease Control and Prevention (CDC). "Stroke." Accessed on July 12, 2016 at <http://www.cdc.gov/stroke/>.
2. Mozaffarian, D., et al. (2016). Heart disease and stroke statistics - 2016 update: a report from the American Heart Association. *Circulation*, 133. Accessed on July 12, 2016 at <http://circ.ahajournals.org.proxy1.athensams.net/content/133/4/e38>.
3. World Health Organization (WHO). Stroke, Cerebrovascular accident. Accessed on May 1, 2014 at http://www.who.int/topics/cerebrovascular_accident/en/
4. World Health Organization (WHO). Global burden of stroke. Accessed on May 2, 2014 at http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf?ua=1.
5. DiCarlo, A. (2009). Human and economic burden of stroke. *Age Ageing*, 38(1):4-5. doi: 10.1093/ageing/afn282. Accessed on May 3, 2014 at <http://ageing.oxfordjournals.org/content/38/1/4.full>.
6. Yang, G., et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. *Lancet*. 2013 Jun 8;381(9882):1987-2015.
7. Go, A.S., et al. Prevalence of Diagnosed Atrial Fibrillation in Adults. *JAMA*. 2001;285:2370-2375.
8. Gattellari, M., Worthington, J.M., Zwar, N.A., & Middleton, S. (2008). The management of non-valvular atrial fibrillation (NVAf) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. *BMC Family Practice*, 9(62). doi: 10.1186/1471-2296-9-62.
9. Ciervo, C.A., et al. Stroke Prevention in Patients With Atrial Fibrillation: Disease Burden and Unmet Medical Needs. *J Am Osteopath Assoc*. 2012;112(9 suppl 2):eS2-eS8.
10. Roger, V.L., et al. Executive summary: heart disease and stroke statistics—2011 update: A Report From the American Heart Association. *Circulation*. 2011;123:459–463.
11. Alonso, A. and Bengtson, L.G.S. (2013). A Rising Tide: The Global Epidemic of Atrial Fibrillation. *Circulation*. doi: 10.1161/CIRCULATIONAHA.113.007482. Accessed on May 13, 2014 at <http://circ.ahajournals.org.proxy1.athensams.net/content/early/2013/12/16/CIRCULATIONAHA.113.007482.full.pdf>.
12. Centers for Disease Control and Prevention. (2011). "Heart Disease and Stroke Prevention: addressing the Nation's Leading Killers, At A Glance 2011. Estimated Direct and Indirect Costs of Major Cardiovascular Diseases United States, 2010". Chronic Disease Prevention and Health Promotion. Accessed on May 13, 2014 at http://www.cdc.gov/chronicdisease/resources/publications/aag/dhdsp_text.htm#2.
13. Murray, C.J.L., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012, 380: 2197-223.
14. Lloyd-Jones D., et al. Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association. *Circulation*. 2010;121:e91.
15. Coyne, K.S., et al., Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. *Value Health*. 2006 Sep–Oct;9(5):348–56.
16. World Health Organization (WHO). (2012). A Comprehensive Global Monitoring Framework, Including Indicators, and a Set of Voluntary Global Targets for the Prevention and Control of Noncommunicable Diseases, Revised WHO Discussion Paper, Version dated 25 July 2012. Accessed on May 3, 2014 at http://www.who.int/nmh/events/2012/discussion_paper3.pdf
17. Cannom, D.S., et al. (2011) ACCF/AHA/HRS Focused Update Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2011;123:e269-e367.
18. Capodanno, D., et al. (2013). Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. *International Journal of Cardiology*, 167:1237-241.

Issued by Global Policy and International Public Affairs

For more information, visit Pfizer.com/ValueOfMedicines

Please follow @pfizer on Twitter, where you can find more information using the hashtag #ValueofMeds

November 2016

Innovation in Pharmacological Treatment

New and innovative medications have been developed to reduce the risk of AF-related stroke, providing prescribers more treatment options to reduce the risk in patients with NVAf. The newer anticoagulant therapies, also known as Novel Oral Anticoagulants or NOACs, work either as direct thrombin inhibitors, which prevents the conversion of fibrinogen to fibrin, or as selective factor Xa inhibitors, which work on the preceding step in the coagulation cascade to prevent the conversion of prothrombin to thrombin. Another goal of these new therapies is to reduce the risk of bleeding, which is a serious and sometimes fatal adverse event of anticoagulants. The results of a large meta-analysis involving over 50,000 patients showed that in patients with NVAf, these newer therapies decreased the risk of stroke; which was mainly driven by fewer hemorrhagic strokes and decrease in mortality.¹⁸ As with any medication, it is important for the physician and patient to carefully evaluate the benefits and risks of any therapy used to treat AF.

Biomedical innovation continues to improve upon noninvasive treatments for patients with AF. The value of medicines in the prevention and treatment of atrial fibrillation of stroke shall also continue to grow, as more older individuals have access to medical care.